Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Liqure Inc. manages a patent portfolio in the Biotechnology & Pharmaceuticals technology area. The prosecution activity is concentrated, as shown by 1 pending office action. This action is assigned to JOHNSON, DANIELLE D, who is the only distinct examiner currently involved. The workload is further localized within 1 distinct art unit.
The busiest examiner for this portfolio is JOHNSON, DANIELLE D, who is responsible for 1 busiest examiner pending office action. This match between the total 1 pending office action and the busiest examiner's workload shows that all current prosecution efforts are handled by this individual. Practitioners should note that with 1 distinct examiner involved, the prosecution strategy is highly centralized. This concentration allows for a direct focus on the specific requirements of the Biotechnology & Pharmaceuticals technology area. The company's intellectual property strategy currently relies on the evaluation of the assigned professional within 1 distinct art unit.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| JOHNSON, DANIELLE D | 1 | 45.0% | +13.2% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18435964 | NUTRACEUTICAL GUMMY COMPOSITIONS AND METHOD OF PREVENTING ALCOHOL OVERCONSUMPTION SYMPTOMS | JOHNSON, DANIELLE D | 131d overdue |
| Art Unit | Apps |
|---|---|
| 1617 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18435964 | NUTRACEUTICAL GUMMY COMPOSITIONS AND METHOD OF PREVENTING ALCOHOL OVERCONSUMPTION SYMPTOMS | JOHNSON, DANIELLE D | 1617 | §103 | Final Rejection | 131d overdue | Pending | Feb 07, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialLiqure Inc. has 1 pending office actions as of November 2026, spread across 1 art units and 1 examiners.
Danielle D Johnson has the most, with 1 of Liqure Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.